Cannabinoid CB 2 receptors in the mouse brain: Relevance for Alzheimer's disease

Journal of Neuroinflammation

Volumn 15, Issue 1, 2018, Pages

  López, Alicia ^a,b   Aparicio, Noelia ^a,c   Pazos, M Ruth ^a,c   Grande, M Teresa ^c   Barreda Manso, M Asunción ^a,c   Benito Cuesta, Irene ^c   Vázquez, Carmen ^a   Amores, Mario ^a   Ruiz Pérez, Gonzalo ^c   García García, Elena ^a   Beatka, Margaret ^d,e   Tolón, Rosa M ^a,c   Dittel, Bonnie N ^d   Hillard, Cecilia J ^e   Romero, Julián ^a,c  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^b UNIVERSIDAD REY JUAN CARLOS   (Spain)

^c UNIVERSIDAD FRANCISCO DE VITORIA   (Spain)

^d BLOOD RESEARCH INSTITUTE   (United States)

^e MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Amyloid; Cannabinoid CB 2 receptor; Enhanced green fluorescent protein; Microglia; Neuroinflammation; Transgenic mice

Indexed keywords

AMYLOID; CANNABINOID 2 RECEPTOR; ENHANCED GREEN FLUORESCENT PROTEIN; INTERLEUKIN 1BETA; ACTIN BINDING PROTEIN; AIF1 PROTEIN, MOUSE; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); CALCIUM BINDING PROTEIN; CD11B ANTIGEN; ENOLASE; GREEN FLUORESCENT PROTEIN; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; BRAIN CORTEX; BRAIN STEM; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; GLIOSIS; HIPPOCAMPUS; MALE; MICROGLIA; MOUSE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PROTEIN EXPRESSION; SENILE PLAQUE; THALAMUS; UPREGULATION; AMYLOID PLAQUE; ANALYSIS OF VARIANCE; ANIMAL; C57BL MOUSE; DISEASE MODEL; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANALYSIS OF VARIANCE; ANIMALS; BRAIN; CALCIUM-BINDING PROTEINS; CD11B ANTIGEN; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GREEN FLUORESCENT PROTEINS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROFILAMENT PROTEINS; PEPTIDE FRAGMENTS; PHOSPHOPYRUVATE HYDRATASE; PLAQUE, AMYLOID; RECEPTOR, CANNABINOID, CB2;

EID: 85047540052     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/s12974-018-1174-9     Document Type: Article

References (40)

1. Aso E, Juvés S, Maldonado R, Ferrer I. CB2 cannabinoid receptor agonist ameliorates Alzheimer-like phenotype in AβPP/PS1 mice. J Alz Dis. 2013;35:847-858.
2. Aso E, Andrés-Benito P, Carmona M, Maldonado R, Ferrer I. Cannabinoid receptor 2 participates in amyloid-β processing in a mouse model of Alzheimer's disease but plays a minor role in the therapeutic properties of a cannabis-based medicine. J Alz Dis. 2016;51:489-500.
3. Atwood BK, Mackie K. CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol. 2010;160:467-79.
4. Bacskai BJ, Klunk WE, Mathis CA, Hyman BT. Imaging amyloid-β deposits in vivo. J Cereb Blood Flow Metab. 2002;22:1035-1041.
5. Benito C, Nunez E, Tolon RM, Carrier EJ, Rabano A, Hillard CJ, Romero J. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J Neurosci. 2003;23:11136-41.
6. Benito C, Tolon RM, Pazos MR, Nuñez E, Castillo AI, Romero J. Cannabinoid CB2 receptors in human brain inflammation. Br J Pharmacol. 2008;153:277-85.
7. Borges da Silva H, Fonseca R, Pereira RM, Cassado Ados A, Álvarez JM, D'Império Lima MR. Splenic macrophage subsets and their function during blood-borne infections. Front Immunol. 2015;6:480.
8. Cabral GA, Ferrerira GA, Jamerson MJ. Endocannabinoids and the immune system in health and disease. Handb Exp Pharmacol. 2015;231:185-211.
9. Carlisle SJ, Marciano-Cabral F, Staab A, Ludwick C, Cabral GA. Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. Int Immunopharmacol. 2002;2:69-82.
10. Esposito G, Iuvone T, Savani C, Scuderi C, De Filippis D, Papa M, DiMarzo V, Steardo L. Opposing control of cannabinoid receptor stimulation on amyloid-beta-induced reactive gliosis: in vitro and in vivo evidence. J Pharmacol Exp Ther. 2007;322:1144-52.
11. Foster DJ, Wilson JM, Remke DH, Mahmood MS, Uddin MJ, Wess J, Patel S, Marnett LJ, Niwswender CM, Jones CK, Xiang Z, Lindsley CW, Rook JM, Conn PJ. Antipsychotic-like effects of M4 positive allosteric modulators are mediated by CB2 receptor-dependent inhibition of dopamine release. Neuron. 2016;91:1244-52.
12. Galiègue S, Mary S, Marchand J, Dussossoy D, Carrière D, Carayon P, Bouaboula M, Shire D, Le Fur G, Casellas P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem. 1995;232:54-61.
13. Gong JP, Onaivi ES, Ishiguro H, Liu QR, Tagliaferro PA, Brusco A, Uhl GR. Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res. 2006;1071:10-23.
14. Heneka MT, Golenbock DT, Latz E. Innate immunity in Alzheimer's disease. Nat Immunol. 2015;16:229-36.
15. Hey YY, O'Neill HC. Murine spleen contains a diversity of myeloid and dendritic cells distinct in antigen presenting function. J Cell Mol Med. 2012;16:2611-9.
16. Koppel J, Vingtdeux V, Marambaud P, D'Abramo C, Jimenez H, Stauber M, Friedman R, Davies P. CB2 receptor deficiency increases amyloid pathology and alters tau processing in a transgenic mouse model of Alzheimer's disease. Mol Med. 2014;20:29-36.
17. Lein ES, et al. Genome-wide atlas of gene expression in the adult mouse brain. Nature. 2007;445:168-76.
18. Lynn AB, Herkenham M. Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. J Pharmacol Exp Ther. 1994;268:1612-23.
19. Maresz K, Carrier EJ, Ponomarev ED, Hillard CJ, Dittel BN. Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. J Neurochem. 2005;95:437-45.
20. Maresz K, Pryce G, Ponomarev ED, Marsicano G, Croxford JL, Shriver LP, Ledent C, Cheng X, Carrier EJ, Mann MK, Giovannoni G, Pertwee RG, Yamamura T, Buckley NE, Hillard CJ, Lutz B, Baker D, Dittel BN. Direct supression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med. 2007;13:492-7.
21. Martín-Moreno AM, Reigada D, Ramírez G, Mechoulam R, Innamorato N, Cuadrado A, de Ceballos ML. Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease. Mol Pharmacol. 2011;79:964-73.
22. Martín-Moreno AM, Brera B, Spuch C, Carro E, García-García L, Delgado M, Pozo MA, Innamorato NG, Cuadrado A, de Ceballos ML. Prolonged oral cannabinoid administration prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in Tg APP2576 mice. J Neuroinflamm. 2012;9:8.
23. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365:61-5.
24. Nuñez E, Benito C, Pazos MR, Barbachano A, Fajardo O, González S, Tolón RM, Romero J. Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: an immunohistochemical study. Synapse. 2004;53:208-13.
25. Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, Berry R, Vassar R. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006;26:10129-40.
26. Ramírez BG, Blázquez C, Gómez del Pulgar T, Guzmán M, de Ceballos ML. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci. 2005;23:1904-13.
27. Ray A, Basu S, Gharalbeth RZ, Cook LC, Kumar R, Lefkowitz EJ, Walker CR, Morrow CD, Franklin CL, Gelger TL, Salzman NH, Fodor A, Dittel BN. Gut microbial dysbiosis due to helicobacter drives an increase in marginal zone B cells in the absence of IL-10 signaling in macrophages. J Immunol. 2015;195:3071-85.
28. Savonenko AV, Melnikova T, Wang Y, Ravert H, Gao Y, Koppel J, Lee D, Pletnikova O, Cho E, Sayyida N, Hiatt A, Troncoso J, Davies P, Dannals RF, Pomper MG, Horti AG. Cannabinoid CB2 receptors in a mouse model of Ab amyloidosis: immunohistochemical analysis and suitability as a PET biomarker of neuroinflammation. PLoS One. 2015;10 https://doi.org/10.1371/journal.pone.0129618. eCollection 2015
29. Schmöle AC, Lundt R, Gennequin B, Schrage H, Beins E, Krämer A, Zimmer T, Limmer A, Zimmer A, Otte DM. Expression analysis of CB2-GFP BAC transgenic mice. PLoS One. 2015a;10 https://doi.org/10.1371/journal.pone.0138986. eCollection 2015
30. Schmöle AC, Lundt R, Ternes S, Albayram Ö, Ulas T, Schultze JL, Bano D, Nicotera P, Alferink J, Zimmer A. Cannabinoid receptor 2 deficiency results in reduced neuroinflammation in an Alzheimer's disease mouse model. Neurobiol Ag. 2015b;36:710-9.
31. Stella N. Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia. 2010;58:1017-30.
32. Stempel AV, Stumpf A, Zhang HY, Özdögan T, Pannasch U, Theis AK, Otte DM, Wojtalla A, Racz I, Ponomarenko A, Xi ZX, Zimmer A, Schimtz D. Cannabinoid type 2 receptors mediate a cell type-specific plasticity in the hippocampus. Neuron. 2016;90:795-809.
33. Tolón RM, Núñez E, Pazos MR, Benito C, Castillo AI, Martínez-Orgado JA, Romero J. The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta-amyloid removal by human macrophages. Brain Res. 2009;1283:148-54.
34. Van der Stelt M, Mazzola C, Esposito G, Matias I, Petrosino S, De Filippis D, Micale V, Steardo L, Drago F, Iuvone T, Di Marzo V. Endocannabinoids and beta-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels. Cell Mol Life Sci. 2006;63:1410-24.
35. Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K, Stella N, Makriyannis A, Piomelli D, Davison JS, Marnett LJ, Di Marzo V, Pittman QJ, Patel KD, Sharkey KA. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science. 2005;310:329-32.
36. Vazquez C, Tolón RM, Grande MT, Caraza M, Moreno M, Koester EC, Villaescusa B, Ruiz-Valdepeñas L, Fernández-Sánchez FJ, Cravatt BF, Hillard CJ, Romero J. Endocannabinoid regulation of amyloid-induced neuroinflammation. Neurobiol Ag. 2015;36:3008-19.
37. Walter L, Franklin A, Witting A, Wade C, Xie Y, Kunos G, Mackie K, Stella N. Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci. 2003;23:1398-405.
38. Wu J, Bie B, Yang H, Xu JJ, Brown DL, Naguib M. Activation of the CB2 receptor system reverses amyloid-induced memory deficiency. Neurobiol Ag. 2013;34:791-804.
39. Zhang HY, Gao M, Liu QR, Bi GH, Li X, Gardner EL, Wu J, Xi ZX. Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice. Proc Natl Acad Sci U S A. 2014;111:E5007-15.
40. Zimmerman AM, Titishov N, Mechoulam R, Zimmerman S. Effect of stereospecific cannabinoids on the immune system. Adv Exp Med Biol. 1991;288:71-80.